P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Intravenous Pembrolizumab Combined with Intravesical Bacillus Calmette–Guérin (BCG) for Patients with BCG-Naïve “Very High-Risk” T1 Non-Muscle Invasive Bladder Cancer Traditionally Reco